二甲双胍预防前列腺癌ADT相关代谢综合征的3期随机试验(PRIME研究)
PRIME研究是一项3期多中心双盲随机对照试验,纳入166例计划接受至少9个月ADT的正常血糖前列腺癌患者,按2:1随机接受二甲双胍850mg每日两次或安慰剂治疗18个月。结果显示二甲双胍未显著降低18个月时代谢综合征比例(55% vs 68%,P=0.2),但显著改善体重、腰围和HbA1c。
要点
- 二甲双胍未降低ADT患者18个月代谢综合征风险(55% vs 68%,P=0.2)。
- 二甲双胍显著减少9个月和12个月体重增加,并降低HbA1c。
- 二甲双胍组9个月和18个月腰围增加幅度显著小于安慰剂组。
核心结论
- 二甲双胍未能降低前列腺癌ADT患者代谢综合征风险。
- 二甲双胍对体重、腰围和HbA1c有显著改善,可能减少ADT相关并发症。
研究设计与样本
- 3期多中心双盲随机对照试验,正常血糖前列腺癌患者计划ADT至少9个月。
- 按2:1随机接受二甲双胍850mg每日两次或安慰剂口服18个月。
- 最终分析纳入二甲双胍组90例和安慰剂组45例,中位随访24个月(IQR 19.5-36)。
主要发现
- HbA1c变化:9个月二甲双胍组-0.02%(0.23%) vs 安慰剂组+0.08%(0.26%),P=0.02;12个月+0.03%(0.27%) vs +0.08%(0.27%),P=0.03。
临床怎么用
- 二甲双胍不应常规用于预防ADT相关代谢综合征。
- 对于ADT治疗中出现体重增加或血糖异常的患者,二甲双胍可能改善代谢指标。
局限性
- 试验因药物供应中止提前终止,未达到计划样本量300例。
- 最终分析样本量较小(二甲双胍组90例,安慰剂组45例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We investigated whether metformin decreases metabolic syndrome (MS) risk in patients with prostate cancer (PCa) receiving androgen deprivation therapy (ADT). MATERIALS AND METHODS: In this phase 3, multicenter, double-blind, randomized controlled trial, normoglycemic patients with PCa planned for at least 9 months of ADT were randomized 2:1 to receive metformin 850 mg or placebo twice daily orally for 18 months. The primary objective was to compare proportions of MS at 18 months between the study arms. RESULTS: Between July 2018 and November 2023, 166 patients were randomized. The trial closed prematurely on November 24, 2023, because of drug supply cessation and the planned enrollment numbers (n = 300) were not met. A total of 90 (metformin) and 45 patients (placebo) were analyzed in the final analysis. The median follow-up was 24 months (IQR: 19.5-36 months). Proportions of MS between metformin and placebo arms were 38/90 (42%) vs 26/45 (58%) at baseline (P = .09) and 40/73 (55%) vs 23/34 (68%) at 18 months (P = .2). Significant reductions in mean (SD) body weight occurred with metformin at 9 (-0.9 [4] vs +1.8 [3.8] kg; P < .001) and 12 months (-0.33 [3.9] vs +1.8 [3.9] kg; P = .004). Mean (SD) hemoglobin A1c was lowered with metformin at 9% (-0.02% [0.23%] vs +0.08% [0.26%]; P = .02) and 12 months (+0.03% [0.27%] vs +0.08% [0.27%]; P = .03). Significantly smaller increments in mean (SD) waist circumferences were noted with metformin at 9 (+0.8 [4.3] vs +2.9 [5.7] cm; P = .03), 12 (+1.9 [5.1] vs +3.3 [6] cm; P = .15), and 18 months (+1.8 [3.8] vs +3.8 [6.1] cm; P = .03). CONCLUSIONS: Metformin did not reduce the risk of MS in patients with PCa on ADT. However, significant improvements in body weight, waist circumference, and hemoglobin A1c suggest a potential role for metformin in reducing ADT-related complications.
引用
- Eigl BJ, Elangovan A, Ghosh S, et al. A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The PRIME Study. J Urol. 2025. PMID: 40711960. doi:10.1097/JU.0000000000004695
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。